清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion

医学 化疗 贝伐单抗 肺癌 内科学 肿瘤科 免疫疗法 癌症
作者
Yue Zheng,Yang Fu,Yueyun Chen,Qing Li,Ting Liu,Zhenyu Ding
出处
期刊:Current Oncology [Multidisciplinary Digital Publishing Institute]
卷期号:30 (11): 9929-9939 被引量:1
标识
DOI:10.3390/curroncol30110721
摘要

Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (n = 31) had poor PFS compared with those without EGFR mutations (n = 141, 5.0 mon and 11.2 mon, p < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (n = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, p = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (n = 54) and those treated with immunochemotherapy (n = 31) was 6.5 mon vs. 5.0 mon (p = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (n = 20) and chemotherapy alone (n = 16) was 8.8 mon and 5.2 mon, respectively (p = 0.082) or immunochemotherapy (n = 15, 8.8 mon and 5.0 mon, p = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, p = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Dr.Tang完成签到 ,获得积分10
6秒前
15秒前
Siren发布了新的文献求助30
19秒前
披着羊皮的狼完成签到 ,获得积分10
53秒前
54秒前
sci完成签到 ,获得积分10
56秒前
1分钟前
酷波er应助科研通管家采纳,获得10
1分钟前
Ava应助科研通管家采纳,获得10
1分钟前
yindi1991完成签到 ,获得积分10
1分钟前
1分钟前
科研通AI5应助Siren采纳,获得10
1分钟前
1分钟前
Siren发布了新的文献求助10
1分钟前
ding应助瑁柏采纳,获得10
1分钟前
瑁柏完成签到,获得积分10
1分钟前
1分钟前
1分钟前
瑁柏发布了新的文献求助10
1分钟前
Siren发布了新的文献求助10
2分钟前
2分钟前
Ggap1发布了新的文献求助10
2分钟前
Ggap1完成签到,获得积分10
2分钟前
思源应助Siren采纳,获得10
3分钟前
Raul完成签到 ,获得积分10
3分钟前
Akim应助科研通管家采纳,获得10
3分钟前
Hello应助科研通管家采纳,获得10
3分钟前
3分钟前
3分钟前
Siren发布了新的文献求助10
3分钟前
Xu完成签到,获得积分20
3分钟前
荣浩宇完成签到 ,获得积分10
3分钟前
3分钟前
科研通AI5应助和谐乌龟采纳,获得10
4分钟前
4分钟前
4分钟前
mo发布了新的文献求助10
4分钟前
4分钟前
雪山飞龙完成签到,获得积分10
4分钟前
4分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968504
求助须知:如何正确求助?哪些是违规求助? 3513331
关于积分的说明 11167297
捐赠科研通 3248697
什么是DOI,文献DOI怎么找? 1794417
邀请新用户注册赠送积分活动 875030
科研通“疑难数据库(出版商)”最低求助积分说明 804664